FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to compounds of formula I, as well as to pharmaceutical compositions based thereon.
EFFECT: technical result is obtaining novel compounds having BACE1 inhibitor activity, useful in therapeutic and/or preventive treatment of mediated diseases.
22 cl, 9 tbl, 44 ex
Title | Year | Author | Number |
---|---|---|---|
2,2,2-TRIFLUOROETHYL-THIADIAZINES | 2015 |
|
RU2692102C2 |
INHIBITORS OF AKT ACTIVITY | 2010 |
|
RU2579513C2 |
NOVEL NICOTINAMIDE DERIVATIVE OR ITS SALT | 2011 |
|
RU2576623C2 |
CONDENSED AMINOHYDROTHIAZINE DERIVATIVE | 2009 |
|
RU2476431C2 |
2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND(OR) BACE2 INHIBITORS | 2010 |
|
RU2515221C2 |
SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIAL AGENTS | 2019 |
|
RU2799335C2 |
PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | 2008 |
|
RU2490265C2 |
2, 5, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-3-YLAMINES OR 2, 3, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-5-YLAMINES | 2011 |
|
RU2570796C2 |
NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
PHARMACEUTICAL COMPOUNDS | 2019 |
|
RU2821941C2 |
Authors
Dates
2020-01-28—Published
2016-03-16—Filed